Durant, S. T. (2018). The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. American Association for the Advancement of Science (AAAS).
Chicago Style (17th ed.) CitationDurant, S. T. The Brain-penetrant Clinical ATM Inhibitor AZD1390 Radiosensitizes and Improves Survival of Preclinical Brain Tumor Models. American Association for the Advancement of Science (AAAS), 2018.
MLA (9th ed.) CitationDurant, S. T. The Brain-penetrant Clinical ATM Inhibitor AZD1390 Radiosensitizes and Improves Survival of Preclinical Brain Tumor Models. American Association for the Advancement of Science (AAAS), 2018.
Warning: These citations may not always be 100% accurate.